NLS Pharma Pins Hopes On Ex-Obesity Drug For ADHD
Emerging Company Profile: NLS Pharma wants to develop novel treatments for ADHD, sleep disorders and cognitive impairments. Its big hope is mazindol CR, for which it has just announced promising Phase II data. The firm explains what is next.
You may also be interested in...
Sunovion is pressing ahead with plans for an FDA filing for its ADHD drug dasotraline in adult and children patients despite ongoing uncertainty over the drug's efficacy in the older grouping.
Patient access schemes have helped the Scottish Medicines Consortium recommend rare disease products, including Regeneron/Sanofi’s Libtayo for skin cancer.
In an exclusive interview, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.